Apollomics

Apollomics ROA

The Return on Assets (ROA) of Apollomics (APLM) as of Oct 19, 2026 is -162.93 %. In the previous year, Return on Assets (ROA) was -411.19 % — a change of -60.38% (higher).

ROA

-162.93 %

YoY

-60.38%

Last updated:

In 2025, Apollomics's return on assets (ROA) was -162.93 %, a -60.38% increase from the -411.19 % ROA in the previous year.

The Apollomics ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
-58.07 USD
Jan 1, 2020
-44.03 USD
Jan 1, 2021
-76.80 USD
Jan 1, 2022
-314.89 USD
Jan 1, 2023
-311.63 USD
Jan 1, 2024
-411.19 USD
Jan 1, 2025
-162.93 USD
The Apollomics ROA history
YEARROAYoY
-162.93 %-60.38%
-411.19 %+31.95%
-311.63 %-1.04%
-314.89 %+310.02%
-76.80 %+74.43%
-44.03 %-24.18%
-58.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apollomics Stock analysis

What does Apollomics do? Apollomics Inc is a clinical-stage biotechnology company based in Foster City, California, operating within the Health Care sector. The company went public via an IPO on November 26, 2021, and is listed under the ticker APLM with ISIN KYG0411D1236. Apollomics focuses on the discovery and development of oncology therapies designed to address unmet medical needs. The company's pipeline includes approximately nine drug candidates, six of which are in clinical development. Its lead program involves vebreltinib (APL-101), a c-Met inhibitor being evaluated in a Phase II multicohort clinical trial for non-small cell lung cancer and other advanced tumors with c-Met alterations. Another key candidate is uproleselan (APL-106), an E-Selectin antagonist under development as an adjunct to standard chemotherapy for acute myeloid leukemia and other hematologic cancers. Apollomics aims to create therapies that can be combined with existing treatments to enhance immune system engagement and target specific molecular pathways in cancer. The company's website is www.apollomicsinc.com. Apollomics is engaged in advancing innovative oncology treatments through clinical research and development. Apollomics is one of the most popular companies on Eulerpool.

ROA Details

Understanding Apollomics's Return on Assets (ROA)

Apollomics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Apollomics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Apollomics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Apollomics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Apollomics stock

Return on Assets (ROA) of Apollomics is -162.93 % in 2025.

Return on Assets (ROA) of Apollomics changed from -411.19 % to -162.93 %, representing a -60.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Apollomics since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Apollomics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Apollomics

All Key Metrics — Apollomics